Literature DB >> 33108630

Ketone Metabolite β-Hydroxybutyrate Ameliorates Inflammation After Spinal Cord Injury by Inhibiting the NLRP3 Inflammasome.

Ganggang Kong1,2, Junhao Liu1, Rong Li1, Junyu Lin1, Zucheng Huang1, Zhou Yang1, Xiuhua Wu1, Zhiping Huang1, Qingan Zhu3, Xiaoliang Wu4.   

Abstract

Ketogenic diet (KD) has been shown to be beneficial in a range of neurological disorders, with ketone metabolite β-hydroxybutyrate (βOHB) reported to block the nucleotide oligomerization domain-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome in bone marrow-derived macrophages. In this study, we show that pretreatment with KD or in situ βOHB suppressed macrophages/microglia activation and the overproduction of inflammatory cytokines, while KD downregulated the expression of NLRP3 inflammasome. Moreover, KD promoted macrophages/microglia transformation from the M1 phenotype to the M2a phenotype following spinal cord injury (SCI) in the in vivo study. Rats in the KD group demonstrated improved behavioral and electrophysiological recovery after SCI when compared to those rats in the standard diet group. The in vitro study performed on BV2 cells indicated that βOHB inhibited an LPS+ATP-induced inflammatory response and decreased NLRP3 protein levels. Our data demonstrated that pretreatment with KD attenuated neuroinflammation following SCI, probably by inhibiting NLRP3 inflammasome and shifting the activation state of macrophages/microglia from the M1 to the M2a phenotype. Therefore, the ketone metabolite βOHB might provide a potential future therapeutic strategy for SCI.

Entities:  

Keywords:  Ketogenic diet; Macrophages/microglia; NLRP3 inflammasome; Spinal cord injury; β-Hydroxybutyrate

Mesh:

Substances:

Year:  2020        PMID: 33108630     DOI: 10.1007/s11064-020-03156-2

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  60 in total

1.  Crocetin Potentiates Neurite Growth in Hippocampal Neurons and Facilitates Functional Recovery in Rats with Spinal Cord Injury.

Authors:  Xiqian Wang; Xiejia Jiao; Zhonghao Liu; Yixin Li
Journal:  Neurosci Bull       Date:  2017-08-02       Impact factor: 5.203

2.  Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord.

Authors:  Kristina A Kigerl; John C Gensel; Daniel P Ankeny; Jessica K Alexander; Dustin J Donnelly; Phillip G Popovich
Journal:  J Neurosci       Date:  2009-10-28       Impact factor: 6.167

Review 3.  Repertoire of microglial and macrophage responses after spinal cord injury.

Authors:  Samuel David; Antje Kroner
Journal:  Nat Rev Neurosci       Date:  2011-06-15       Impact factor: 34.870

4.  CD200 modulates spinal cord injury neuroinflammation and outcome through CD200R1.

Authors:  Natalia Lago; Bruno Pannunzio; Jesús Amo-Aparicio; Rubèn López-Vales; Hugo Peluffo
Journal:  Brain Behav Immun       Date:  2018-06-02       Impact factor: 7.217

Review 5.  Acute Spinal Cord Injury.

Authors:  Christopher D Witiw; Michael G Fehlings
Journal:  J Spinal Disord Tech       Date:  2015-07

Review 6.  Macrophage activation and its role in repair and pathology after spinal cord injury.

Authors:  John C Gensel; Bei Zhang
Journal:  Brain Res       Date:  2015-01-08       Impact factor: 3.252

Review 7.  Spinal cord injury-induced pain: mechanisms and treatments.

Authors:  Philip J Siddall; James W Middleton
Journal:  Pain Manag       Date:  2015-09-24

8.  Inhibition of EGFR/MAPK signaling reduces microglial inflammatory response and the associated secondary damage in rats after spinal cord injury.

Authors:  Wen-Sheng Qu; Dai-Shi Tian; Zhi-Bao Guo; Jun Fang; Qiang Zhang; Zhi-Yuan Yu; Min-Jie Xie; Hua-Qiu Zhang; Jia-Gao Lü; Wei Wang
Journal:  J Neuroinflammation       Date:  2012-07-23       Impact factor: 8.322

Review 9.  Global prevalence and incidence of traumatic spinal cord injury.

Authors:  Anoushka Singh; Lindsay Tetreault; Suhkvinder Kalsi-Ryan; Aria Nouri; Michael G Fehlings
Journal:  Clin Epidemiol       Date:  2014-09-23       Impact factor: 4.790

10.  Acute Penicillium marneffei infection stimulates host M1/M2a macrophages polarization in BALB/C mice.

Authors:  Xiaoying Dai; Congzheng Mao; Xiuwan Lan; Huan Chen; Meihua Li; Jing Bai; Jingmin Deng; Qiuli Liang; Jianquan Zhang; Xiaoning Zhong; Yi Liang; Jiangtao Fan; Honglin Luo; Zhiyi He
Journal:  BMC Microbiol       Date:  2017-08-18       Impact factor: 3.605

View more
  6 in total

1.  Ketogenic diet ameliorates inflammation by inhibiting the NLRP3 inflammasome in osteoarthritis.

Authors:  Ganggang Kong; Jinyang Wang; Rong Li; Zhiping Huang; Le Wang
Journal:  Arthritis Res Ther       Date:  2022-05-18       Impact factor: 5.606

Review 2.  Potential Roles of Exercise-Induced Plasma Metabolites Linking Exercise to Health Benefits.

Authors:  Yong Ryoul Yang; Ki-Sun Kwon
Journal:  Front Physiol       Date:  2020-12-03       Impact factor: 4.566

Review 3.  Ketone Supplementation: Meeting the Needs of the Brain in an Energy Crisis.

Authors:  Angela M Poff; Sara Moss; Maricel Soliven; Dominic P D'Agostino
Journal:  Front Nutr       Date:  2021-12-23

4.  Entinostat Improves Motor Function and Neuronal Damage Via Downregulating NLRP3 Inflammasome Activation After Spinal Cord Injury.

Authors:  Chen Dai; Bin Liu; Bibo Peng; Bo Qu; Jiezhi Lin; Baogan Peng; Duan-Ming Li
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

5.  The Anti-Inflammatory Effect of Preventive Intervention with Ketogenic Diet Mediated by the Histone Acetylation of mGluR5 Promotor Region in Rat Parkinson's Disease Model: A Dual-Tracer PET Study.

Authors:  Yuankai Zhu; Xiangyu Tang; Zhaoting Cheng; Qingjian Dong; Ge Ruan
Journal:  Parkinsons Dis       Date:  2022-09-05

Review 6.  Pharmacological and non-pharmacological therapeutic interventions for the treatment of spinal cord injury-induced pain.

Authors:  Olivia C Eller; Adam B Willits; Erin E Young; Kyle M Baumbauer
Journal:  Front Pain Res (Lausanne)       Date:  2022-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.